厦门大学健康医疗大数据研究院
健康医疗大数据国家研究院 | 数字福建健康医疗大数据研究所
National Institute for Data Science in Health and Medicine,Xiamen University
语言选择: 中文简体中文版 ∷  ENGLISH英文版
您的位置: 首页 > 教师队伍 > 教师队伍 > 正文 >
李奇渊

李奇渊  教授,博士生导师

学科(方向):转化医学/计算生物学/基因组学

办公电话:0592-2185175

邮箱:qiyuan.li@xmu.edu.cn

主要经历:

1996~2000 华东理工大学 本科;

2000~2003 厦门大学 细胞生物学 硕士;

2004~2006 丹麦科技大学 生物信息学 硕士;

2006~2010 丹麦科技大学 系统生物学 博士。

2010.03~2012.03 哈佛癌症中心 博士后;

2012.05~2017.11 厦门大学医学院 副教授;

2017.11~至今 厦门大学医学院 教授;

2015~至今 挂职担任厦门大学附属第一医院儿内科科研副主任,开展儿科遗传性缺陷筛查和科研支撑工作;

2016~至今 挂职担任卫计委健康医疗大数据管理中心主任。负责建立人口健康大数据应用开放平台,支持儿科智能化研究。

2018.9至今 厦门大学健康医疗大数据国家研究院副院长

研究领域:

主要从事针对肿瘤基因组的转化医学研究,运用统计学模型从遗传多态性,体细胞变异,表观基因组学和基因表达等多组学数据中寻找与肿瘤分型,预后,靶向治疗敏感性等临床特征有关的决定因子并解释其调控机制;在此基础上建立基于多组学关联的复杂网络模型,应用人工智能方法发现新的肿瘤驱动基因。

代表性成果:

1. Li Y, Zou L, Li Q, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer[J]. Nature Medicine, 2010, 16(2):214.

2. Li Q, Birkbak N J, Balazs G, et al. Jetset: selecting the optimal microarray probe set to represent a gene[J]. BMC Bioinformatics,12,1(2011-12-15), 2011, 12(1):1-7.

3. Li Q, Eklund A C, Birkbak N J, et al. Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response[J]. Bmc Bioinformatics, 2011, 12(1):310.

4. Li Q, Seo J H, Stranger B, et al. Integrative eQTL-Based Analyses Reveal the Biology of Breast Cancer Risk Loci[J]. Cell, 2013, 152(3):633-41.

5. Seo J H, Li Q, Fatima A, et al. Deconvoluting complex tissues for expression quantitative trait locus-based analyses[J]. Philosophical Transactions of the Royal Society of London, 2013, 368(1620):20120363.

6. Li Q, Stram A, Chen C, et al. Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types[J]. Human Molecular Genetics, 2014, 23(19):5294-302.

7. Lawrenson K, Li Q, Kar S, et al. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer[J]. Nature Communications, 2015, 6:8234

主持过的重要课题:

1. 复发性体细胞变异对肿瘤基因表达的决定作用及其分子机制

已申请的专利:

1. 实体肿瘤的临床预后基因标签, 美国专利申请号 No. 61/175,781

所有论文列表:

1.Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S; EMBRACE, Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM; GEMO Study Collaborators, Damiola F, Mazoyer S, Stoppa-Lyonnet D, Claes K, De Leeneer K, Kirk J, Rodriguez GC, Piedmonte M, O'Malley DM, de la Hoya M, Caldes T, Aittomäki K, Nevanlinna H, Collée JM, Rookus MA, Oosterwijk JC; Breast Cancer Family Registry, Tihomirova L, Tung N, Hamann U, Isaccs C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB; HEBON, Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira MR; KConFab Investigators, Pankratz VS, Wang X, Lindor N, Szabo CI, Kauff N, Vijai J, Aghajanian CA, Pfeiler G, Berger A, Singer CF, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Tchatchou S, Andrulis IL, Glendon G, Toland AE, Jensen UB, Kruse TA, Thomassen M, Bojesen A, Zidan J, Friedman E, Laitman Y, Soller M, Liljegren A, Arver B, Einbeigi Z, Stenmark-Askmalm M, Olopade OI, Nussbaum RL, Rebbeck TR, Nathanson KL, Domchek SM, Lu KH, Karlan BY, Walsh C, Lester J; Australian Cancer Study (Ovarian Cancer Investigators); Australian Ovarian Cancer Study Group, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, Chang-Claude J, Wang-Gohrke S, Eilber U, Moysich KB, Odunsi K, Sucheston L, Lele S, Wilkens LR, Goodman MT, Thompson PJ, Shvetsov YB, Runnebaum IB, Dürst M, Hillemanns P, Dörk T, Antonenkova N, Bogdanova N, Leminen A, Pelttari LM, Butzow R, Modugno F, Kelley JL, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Matsuo K, Hosono S, Orsulic S, Jensen A, Kjaer SK, Hogdall E, Hasmad HN, Azmi MA, Teo SH, Woo YL, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Bruinsma F, Giles GG, Liang D, Hildebrandt MA, Wu X, Levine DA, Bisogna M, Berchuck A, Iversen ES, Schildkraut JM, Concannon P, Weber RP, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, Olson SH, Krakstad C, Salvesen HB, Tangen IL, Bjorge L, van Altena AM, Aben KK, Kiemeney LA, Massuger LF, Kellar M, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Cybulski C, Yang H, Lissowska J, Brinton LA, Wentzensen N, Hogdall C, Lundvall L, Nedergaard L, Baker H, Song H, Eccles D, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Ji BT, Zheng W, Shu XO, Gao YT, Rosen B, Risch HA, McLaughlin JR, Narod SA, Monteiro AN, Chen A, Lin HY, Permuth-Wey J, Sellers TA, Tsai YY, Chen Z, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Harrington P, Lee AW, Wu AH, Pearce CL, Coetzee G, Pike MC, Dansonka-Mieszkowska A, Timorek A, Rzepecka IK, Kupryjanczyk J, Freedman M, Noushmehr H, Easton DF, Offit K, Couch FJ, Gayther S, Pharoah PP, Antoniou AC, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1 and BRCA2. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015 Feb;47(2):164-71.

2.Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Røder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokołorczyk D, Kluźniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, Ma J, Stampfer M, Penney KL, Mucci L, John EM, Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM, Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C, Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D, Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ, Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; COGS (Collaborative Oncological Gene-environment Study) Consortium; GAME-ON/ELLIPSE Consortium, Cook MB, Nakagawa H, Wiklund F, Kraft P, Chanock SJ, Henderson BE, Easton DF, Eeles RA, Haiman CA. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014 Oct;46(10):1103-9.

3.Li Q, Stram A, Chen C, Kar S, Gayther S, Pharoah P, Haiman C, Stranger B, Kraft P, Freedman ML. Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types. Hum Mol Genet. 2014 Oct 1;23(19):5294-302.

4.Seo JH, Li Q, Fatima A, Eklund A, Szallasi Z, Polyak K, Richardson AL, Freedman ML. Deconvoluting complex tissues for expression quantitative trait locus-based analyses.Philos Trans R Soc Lond B Biol Sci. 2013 May 6;368(1620):20120363. doi: 10.1098/rstb.2012.0363.

5.Li Q, Seo JH, Stranger B, McKenna A, Pe'er I, LaFramboise T, Brown, M, Tyekucheva S, Freedman ML. Integrative eQTL-Based Analyses Reveal the Biology of Breast Cancer Risk Loci. Cell 2013, 152(3):633

6.Li Q, Birkbak NJ, Gyorffy B, Szallasi1 Z and Aron CE: Jetset: the optimal microarray probe set to represent a gene. BMC Bioinformatics 2011, 12:474

7.Li Q, Eklund AC, Birkbak NJ, Desmedt C, Haibe-Kain B, Sotiriou C, Symmans W. F, Pusztai L, Brunak S, Richardson AL, Szallasi Z: Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response BMC Bioinformatics. BMC Bioinformatics 2011, 12:310

8.Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, Hardcastle T, Lee A, Roy R, East P, Kschischo M, Endesfelder D, Wylie P, Kim SN, Chen JG, Howell M, Ried T, Habermann JK, Auer G, Brenton JD, Szallasi Z, Downward J: Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A 2009, 106(21):8671-8676.

9.Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, Tan IB, Richardson AL, Szallasi Z, Swanton C: Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 2011, 71(10):3447-3452.

10.Li Q, Eklund AC, Juul N, Haibe-Kains B, Workman CT, Richardson AL, Szallasi Z, Swanton C: Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status. PLoS One 2010, 5(12):e15031.

11.Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C: Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 2010, 11(4):358-365.

12.Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC: Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010, 16(2):214-218.

13.Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE: Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28(7):1145-1153.

14.Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010, 123(3):725-731.

15.Li Q, Jorgensen FS, Oprea T, Brunak S, Taboureau O: hERG classification model based on a combination of support vector machine method and GRIND descriptors. Mol Pharm 2008, 5(1):117-127.